These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2063 related articles for article (PubMed ID: 19018742)

  • 1. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
    Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-line haemodiafiltration improves response to calcifediol treatment.
    Pérez-García R; Albalate M; de Sequera P; Alcázar R; Puerta M; Ortega M; Corchete E
    Nefrologia; 2012 Jul; 32(4):459-66. PubMed ID: 22652556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal osteodystrophy Guidelines].
    Messa P;
    G Ital Nefrol; 2003; 20 Suppl 24():S83-95. PubMed ID: 14666505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
    Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V
    Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T; Ritz E; Passlick-Deetjen J
    Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
    Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
    Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 104.